Effect of CX-4945, a selective bioavailable small molecule inhibitor of protein kinase CK2, on gemcitabine antitumor activity in A2780 ovarian cancer.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. e13522-e13522 ◽  
Author(s):  
K. L. Anderes ◽  
N. Streiner ◽  
M. Omori ◽  
N. Huser ◽  
C. Ho ◽  
...  
2013 ◽  
Author(s):  
Amol Padgaonkar ◽  
Olga Rechkoblit ◽  
Stephen Cosenza ◽  
Venkat R. Pallela ◽  
Venkata Subbaiah DRC ◽  
...  

2010 ◽  
Vol 9 (5) ◽  
pp. 1136-1146 ◽  
Author(s):  
Kuzhuvelil B. Harikumar ◽  
Ajaikumar B. Kunnumakkara ◽  
Nobuo Ochi ◽  
Zhimin Tong ◽  
Amit Deorukhkar ◽  
...  

2021 ◽  
Author(s):  
G. Diluvio ◽  
T. T. Kelley ◽  
M. Lahiry ◽  
A. Alvarez Trotta ◽  
E. M. Kolb ◽  
...  

Abstract Notch Activation Complex Kinase, NACK, is a component of the Notch transcriptional machinery critical to Notch-mediated tumorigenesis. However, the mechanism by which NACK regulates the Notch-mediated transcription is not well understood. Here we demonstrate that NACK binds and hydrolyses ATP and that only ATP-bound NACK is able to bind to the Notch Ternary Complex (NTC). Considering this we sought to identify inhibitors of this ATP-Dependent function and, using computational pipelines, discovered the first small molecule inhibitor of NACK, Z271-0326, that directly blocks the activity of Notch-mediated transcription and shows potent antitumor activity in PDX mouse models. In conclusion, we have discovered the first inhibitor that holds promise for efficacious treatment of Notch-driven cancers by blocking the Notch downstream NTC activity.


Sign in / Sign up

Export Citation Format

Share Document